ORAGENICS, INC. Capital Expenditures
ORAGENICS, INC. (OGEN) reported Capital Expenditures of $127.52 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-29.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2024-03-29
- ORAGENICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2022-12-31 was $3.44K, a 82.60% decline year-over-year.
- ORAGENICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2022-09-30 was $37.03K.
- ORAGENICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2022-06-30 was $0.00.
- ORAGENICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2022-03-31 was $87.05K.
- ORAGENICS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $127.52K, a 190.63% increase from fiscal 2021.
- ORAGENICS, INC. payments to acquire property, plant, and equipment for fiscal 2021 was $43.88K.
- ORAGENICS, INC. payments to acquire property, plant, and equipment for fiscal 2019 was $25.21K, a 79.78% decline from fiscal 2018.
- ORAGENICS, INC. payments to acquire property, plant, and equipment for fiscal 2018 was $124.73K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2022-12-31 | $3.44K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $40.47K derived: sum of 2 quarters · filed 2024-03-29 | $40.47K derived: sum of 3 quarters · filed 2024-03-29 | $127.52K 10-K · filed 2024-03-29 |
| 2022-09-30 | $37.03K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $37.03K derived: sum of 2 quarters · filed 2023-11-09 | $124.08K 10-Q · filed 2023-11-09 | $143.83K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $87.05K 10-Q · filed 2023-08-11 | $106.80K derived: sum of 3 quarters · filed 2023-08-11 | |
| 2022-03-31 | $87.05K 10-Q · filed 2023-05-12 | $106.80K derived: sum of 2 quarters · filed 2023-05-12 | ||
| 2021-12-31 | $19.75K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-04-17 | $43.88K 10-K · filed 2023-04-17 | ||
| 2021-09-30 | $24.12K 10-Q/A · filed 2023-04-14 | |||
| 2019-12-31 | $13.86K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $13.86K derived: sum of 2 quarters · filed 2021-03-01 | $25.21K 10-K · filed 2021-03-01 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $11.35K 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $11.35K 10-Q · filed 2020-08-14 | |||
| 2018-12-31 | $64.48K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-04 | $124.73K 10-K · filed 2020-03-04 | ||
| 2018-09-30 | $60.24K 10-Q · filed 2019-11-14 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $27.18K 10-K · filed 2018-02-16 | ||
| 2016-09-30 | $27.18K 10-Q · filed 2017-10-31 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $8.62K derived: sum of 2 quarters · filed 2017-02-27 | $30.27K derived: sum of 3 quarters · filed 2017-02-27 | $102.51K 10-K · filed 2017-02-27 |
| 2015-09-30 | $8.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $30.27K derived: sum of 2 quarters · filed 2016-11-14 | $102.51K 10-Q · filed 2016-11-14 | $193.06K derived: sum of 4 quarters · filed 2016-11-14 |
| 2015-06-30 | $21.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $93.89K 10-Q · filed 2016-08-15 | $184.43K derived: sum of 3 quarters · filed 2016-08-15 | $185.67K derived: sum of 4 quarters · filed 2016-08-15 |
| 2015-03-31 | $72.24K 10-Q · filed 2016-05-16 | $162.78K derived: sum of 2 quarters · filed 2016-05-16 | $164.02K derived: sum of 3 quarters · filed 2016-05-16 | $164.02K derived: sum of 4 quarters · filed 2016-05-16 |
| 2014-12-31 | $90.54K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $91.78K derived: sum of 2 quarters · filed 2016-03-30 | $91.78K derived: sum of 3 quarters · filed 2016-03-30 | $110.67K 10-K · filed 2016-03-30 |
| 2014-09-30 | $1.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $1.24K derived: sum of 2 quarters · filed 2015-11-06 | $20.13K 10-Q · filed 2015-11-06 | $21.29K derived: sum of 4 quarters · filed 2015-11-06 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $18.89K 10-Q · filed 2015-08-07 | $20.05K derived: sum of 3 quarters · filed 2015-08-07 | $31.32K derived: sum of 4 quarters · filed 2015-08-07 |
| 2014-03-31 | $18.89K 10-Q · filed 2015-05-08 | $20.05K derived: sum of 2 quarters · filed 2015-05-08 | $31.32K derived: sum of 3 quarters · filed 2015-05-08 | |
| 2013-12-31 | $1.16K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $12.44K derived: sum of 2 quarters · filed 2015-02-27 | $18.81K 10-K · filed 2015-02-27 | |
| 2013-09-30 | $11.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-03 | $17.65K 10-Q · filed 2014-11-03 | ||
| 2013-06-30 | $6.37K 10-Q · filed 2014-08-07 | |||
| 2012-12-31 | $11.10K 10-K · filed 2014-02-28 | |||
| 2011-06-30 | $0.00 10-Q · filed 2011-08-05 | |||
| 2010-12-31 | -$91.30K derived: 10-K 12 month − 10-Q 9 month · filed 2012-04-16 | $81.89K derived: sum of 2 quarters · filed 2012-04-16 | $88.08K 10-K · filed 2012-04-16 | |
| 2010-09-30 | $173.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | $179.38K 10-Q · filed 2011-11-14 | ||
| 2010-06-30 | $6.20K 10-Q · filed 2011-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |